Filing identity and reporting period
The supplied filing is Rexahn Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2015—not an Opus Genetics, Inc. filing. The company and period therefore do not match the request metadata. The summary below reflects the filing text.
Business context and financial performance
Rexahn described itself as a clinical-stage biopharmaceutical company developing cancer treatments. It reported no revenue and no commercial product sales. Its pipeline included one oncology candidate in Phase II, two in Phase I, and other compounds in preclinical development.
| Metric | Three months ended September 30, 2015 | Nine months ended September 30, 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.10 million | $9.23 million |
| General and administrative expense | $1.55 million | $4.66 million |
| Net loss | $4.03 million | $11.53 million |
| Net loss per share, basic and diluted | $0.02 | $0.06 |
At September 30, 2015, cash and cash equivalents were $12.45 million and marketable securities were $9.01 million, totaling $21.46 million. Total current assets were $22.93 million; current liabilities were $5.37 million. Total liabilities were $5.37 million, including $1.48 million of warrant liabilities; the filing’s balance sheet does not list conventional borrowings or debt.
For the first nine months of 2015, operating cash use was $12.94 million, investing activities provided $13.83 million (mainly from marketable-security redemptions), and financing activities provided $1.74 million. Cash increased $2.62 million from year-end 2014 to $12.45 million.
Changes versus comparable periods
- Third-quarter net loss increased to $4.03 million from $1.91 million in 2014, while nine-month net loss declined to $11.53 million from $16.31 million. The year-to-date comparison was affected substantially by warrant fair-value changes: a $2.28 million gain in 2015 versus a $6.79 million loss in 2014.
- R&D expense rose 70% in the quarter and 92% for the nine months, primarily as clinical candidates advanced, with increased trial, drug-manufacturing, and personnel costs.
- G&A expense rose 18% in the quarter and 1% for the nine months. Management cited increased professional fees, insurance, and personnel costs.
- Operating cash use increased to $12.94 million from $8.13 million for the first nine months of 2014. Financing cash inflows fell to $1.74 million from $24.84 million, as the prior-year period included a registered direct offering.
- Cash and marketable securities declined from $32.70 million at December 31, 2014 to $21.46 million at September 30, 2015; marketable securities alone fell from $22.87 million to $9.01 million.
Outlook, commentary, and risks
Management stated that cash, cash equivalents, and marketable securities were expected to fund current activities for at least the next 12 months. The company also said it would need additional capital to continue development and warned that financing might not be available on acceptable terms; absent sufficient funding, it could reduce R&D programs, beginning with preclinical work. The company anticipated continuing losses.
Management reported preliminary clinical observations, not established efficacy: RX-3117 was described as appearing tolerable at tested doses, with tumor reduction in one patient and stable disease in five; Supinoxin was described as appearing tolerable, with stable disease in four patients at the reported follow-up. The company had modified dosing schedules for both trials. It planned to complete the initial safety component of the Archexin renal-cell-carcinoma study by year-end 2015 and was discussing potential collaborations for RX-3117 and Supinoxin.
Key risks include clinical-trial and regulatory uncertainty, reliance on third-party research organizations and manufacturers, the need for additional capital, and uncertainty over development costs and commercialization timing. Estimated remaining costs under R&D vendor contracts were approximately $10.18 million. A $1.0 million KRICT milestone payment and milestone payments under two drug-delivery-platform licenses had not been triggered as of September 30, 2015. Management said disclosure controls were effective and that there were no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer and filing: the supplied text identifies Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Assess the cash runway against the reported $12.94 million nine-month operating cash use and the company’s stated 12-month funding estimate.
- Review subsequent financing, ATM sales, dilution, and whether additional capital was raised after September 30, 2015.
- Verify the status and results of clinical trials, including the reported preliminary patient observations and dosing changes.
- Evaluate the warrant-liability valuation: the reported $2.28 million nine-month gain was noncash and materially affected the year-over-year net-loss comparison.